Key result
Subclinical AF in hypertrophic cardiomyopathy lacks evidence on significance and management despite ~25% symptomatic prevalence.
Why the study?
There is little data on the significance, prevalence, and management of subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy.
Highlights the need for further research on the significance, prevalence, and management of subclinical atrial fibrillation in patients with hypertrophic cardiomyopathy.
Subclinical AF in HCM lacks evidence on significance and management; leaves open the need for dedicated prevalence and outcome studies.
Atrial fibrillation (AF) is the most common arrhythmia in patients with hypertrophic cardiomyopathy (HCM), with a reported prevalence of AF in HCM of about 25 %.1 Patients with AF in HCM tend to be more symptomatic and have an increased stroke risk compared with patients without HCM.2 While the occurrence and treatment of (symptomatic) AF in HCM have been extensively studied, there is little data on the significance, prevalence, and management of subclinical AF in HCM.
No takes yet. Share an insight, caveat, or question.
Thyagarajan et al. (2016) conducted a review in Hypertrophic Cardiomyopathy and Subclinical Atrial Fibrillation. While symptomatic atrial fibrillation in hypertrophic cardiomyopathy is well-studied with a prevalence of about 25%, there is little data on the significance and management of subclinical AF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: